Michael Dube
Infectious Disease · Los Angeles, CANPI 1134185887
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Merck at 33.3% of the total. 2025 is the largest year on record at $131, 3.8 times the $35 reported in 2019. That places this record below the midpoint for infectious disease clinicians in CA, where the typical reported total is $297.
Across 9 payments — averaging $42.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$127
- Shionogi Inc$125
- Abbott$37
- Gilead$35
- Biofire Diagnostics, LLC$31
- Viiv Healthcare Company$27
Across 32 payments — averaging $23,188 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$607K
- Roche Molecular Systems, Inc.$107K
- Gen-probe, Inc.$24K
- Biofire Diagnostics, LLC$5K
What the payments were for
- Food & beverage$382100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 4 | $127 |
| Shionogi Inc | 1 | $125 |
| Abbott | 1 | $37 |
| Gilead | 1 | $35 |
| Biofire Diagnostics, LLC | 1 | $31 |
| Viiv Healthcare Company | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fetroja$125
How this compares
$382 in reported general payments places this provider in the 50th percentile of 856 infectious disease providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 12 | $43,592 |
| Rosuvastatin Calcium | 15 | $61 |
| Tamsulosin Hcl | 13 | $38 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $35 | $43,59212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 856 infectious disease providers in California.
Other infectious disease in Los Angeles
- Jay GladsteinLos Angeles$657K
- Otto YangLos Angeles$472K
- Irving PosalskiLos Angeles$234K
- Peter RuaneLos Angeles$174K
- Raphael LandovitzLos Angeles$147K
- Jeffrey KlausnerLos Angeles$126K
- Harold Glenn San AgustinLos Angeles$82K
- Fred SattlerLos Angeles$63K
- Judith CurrierLos Angeles$32K
- David HaakeLos Angeles$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.